Active Ingredient History
Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is named after its inventors Albert Calmette and Camille Guérin. In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized, but are frequently exposed, may be immunized, as well. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacterial infections. Additionally, it is sometimes used as part of the treatment of bladder cancer. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Tuberculosis (approved 1927)
Absenteeism (Phase 4)
Alzheimer Disease (Phase 2)
Antineoplastic Agents (Phase 1/Phase 2)
BCG Vaccine (Phase 4)
Blindness (Phase 4)
Breast Neoplasms (Phase 1)
Carcinoma, Transitional Cell (Phase 4)
Cognitive Dysfunction (Phase 2)
Colorectal Neoplasms (Phase 3)
Coronary Disease (Phase 4)
Coronavirus (Phase 4)
Coronavirus Infections (Phase 4)
COVID-19 (Phase 4)
COVID-19 Vaccines (Phase 2)
Dementia (Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Diarrhea (Phase 3)
Eczema (Phase 3)
Endoscopy (Phase 2)
Epigenomics (Phase 4)
Epithelial Cells (Phase 2)
Fibromyalgia (Phase 2)
Healthy Volunteers (Phase 3)
Hemophilia A (Phase 2)
HIV (Phase 2)
HIV Infections (Phase 2)
Hospitalization (Phase 4)
Hypersensitivity (Phase 3)
Immunity (Phase 4)
Immunity, Cellular (Phase 2)
Immunity, Heterologous (Phase 4)
Immunity, Innate (Phase 4)
Immunization (Phase 4)
Immunosenescence (Phase 3)
Infant (Phase 4)
Infant Death (Phase 4)
Infant Mortality (Phase 4)
Infections (Phase 4)
Influenza, Human (Phase 2/Phase 3)
Latent Tuberculosis (Phase 4)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 1/Phase 2)
Malaria (Phase 4)
Malaria, Falciparum (Early Phase 1)
Measles (Phase 4)
Melanoma (Phase 2/Phase 3)
Morbidity (Phase 4)
Mortality (Phase 4)
Mother-Child Relations (Phase 4)
Multiple Sclerosis (Phase 2/Phase 3)
Mycobacterium bovis (Phase 4)
Neonatology (Phase 4)
Neoplasms (Phase 3)
Neoplasms by Site (Phase 3)
Oligospermia (Phase 4)
Ovarian Neoplasms (Phase 2)
Perinatal Death (Phase 4)
Plasmodium falciparum (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Respiratory Syncytial Virus Infections (Phase 1)
Respiratory Tract Infections (Phase 4)
Risk Factors (Phase 2)
Safety (Phase 1/Phase 2)
Sepsis (Phase 3)
Severe Acute Respiratory Syndrome (Phase 3)
Small Cell Lung Carcinoma (Phase 3)
Tuberculosis (Phase 4)
Urinary Bladder Diseases (Phase 3)
Urinary Bladder Neoplasms (Phase 4)
Urogenital Neoplasms (Phase 3)
Urologic Diseases (Phase 3)
Urologic Neoplasms (Phase 3)
Vaccine-Preventable Diseases (Phase 4)
Vaccines (Phase 4)
Virus Diseases (Phase 4)
Whooping Cough (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
